Cargando…

An Assessment of the Bivalent Vaccine as a Second Booster for COVID-19

Detalles Bibliográficos
Autores principales:	Gupta, Sneh Lata, Jaiswal, Rishi K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863048/ https://www.ncbi.nlm.nih.gov/pubmed/36679924 http://dx.doi.org/10.3390/vaccines11010079

Ejemplares similares

Role of Immunoglobulin A in COVID-19 and Influenza Infections
por: Tyagi, Rohit, et al.
Publicado: (2023)

An assessment of the strategy and status of COVID-19 vaccination in India
por: Gupta, Sneh Lata, et al.
Publicado: (2023)

Neutralizing antibody: a savior in the Covid-19 disease
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy
por: Della Polla, Giorgia, et al.
Publicado: (2023)

Axillary lymphadenopathy following bivalent COVID-19 booster vaccination
por: Lane, Elizabeth G., et al.
Publicado: (2023)

A Bivalent Omicron-Containing Booster Vaccine against Covid-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

Relevant of neutralizing antibody during SARS-CoV-2 infection and their therapeutic usage
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies
por: Carreño, Juan Manuel, et al.
Publicado: (2023)

Safety, Tolerability, and Immunogenicity of COVID-19 Bivalent Vaccination
por: Saxena, Divyasha, et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2023)

COVID-19 Bivalent Booster Vaccination Coverage and Intent to Receive Booster Vaccination Among Adolescents and Adults — United States, November–December 2022
por: Lu, Peng-jun, et al.
Publicado: (2023)

Characterizing healthcare worker attitudes toward the bivalent COVID-19 booster
por: Willebrand, Kathryn, et al.
Publicado: (2023)

LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

EE329 The Value-Based Price for a Bivalent COVID-19 Booster Vaccine in the United Kingdom
por: Kohli, M., et al.
Publicado: (2023)

Children’s SARS-CoV-2 Infection and Their Vaccination
por: Gupta, Sneh Lata, et al.
Publicado: (2023)

Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations
por: Stoliaroff-Pepin, Anna, et al.
Publicado: (2023)

Estimated US Pediatric Hospitalizations and School Absenteeism Associated With Accelerated COVID-19 Bivalent Booster Vaccination
por: Fitzpatrick, Meagan C., et al.
Publicado: (2023)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

COVID-19 vaccine equity and booster doses
por: The Lancet Infectious Diseases
Publicado: (2021)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Immunotherapy: an alternative promising therapeutic approach against cancers
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations
por: Alcendor, Donald J., et al.
Publicado: (2023)

2334. The effectiveness of bivalent COVID-19 booster among patients with hematologic malignancies
por: Aleissa, Muneerah M, et al.
Publicado: (2023)

Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol
por: Tan, Ngoc H., et al.
Publicado: (2022)

Effectiveness of Bivalent Boosters against Severe Omicron Infection
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Why promoting a COVID-19 vaccine booster dose?
por: Loubet, Paul, et al.
Publicado: (2021)

Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination
por: Jacobs, Jeremy W., et al.
Publicado: (2023)

The pros and cons of the second booster dose of the COVID-19 vaccine
por: Mostafavi, Ehsan
Publicado: (2022)

Efficacy of the Second COVID-19 Vaccine Booster Dose in the Elderly
por: Mattiuzzi, Camilla, et al.
Publicado: (2023)

(8) 5th Dose Bivalent Omicron-Containing Booster Vaccine Against Covid-19 in Heart Transplant Recipients
por: Peled, Y., et al.
Publicado: (2023)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Reasons for Receiving or Not Receiving Bivalent COVID-19 Booster Vaccinations Among Adults — United States, November 1–December 10, 2022
por: Sinclair, Alyssa H., et al.
Publicado: (2023)

Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study
por: Arbel, Ronen, et al.
Publicado: (2023)

Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster
por: Jabagi, Marie-Joelle, et al.
Publicado: (2023)

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
por: Chalkias, Spyros, et al.
Publicado: (2022)

COVID-19 Booster Vaccination Bellwethers: Factors Predictive of Older Adults’ Adoption of the Second Booster COVID-19 Vaccine in Israel: A Longitudinal Study
por: Ben-David, Boaz M., et al.
Publicado: (2023)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

COVID-19 vaccine boosters: What do we know so far?
por: Kherabi, Yousra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_824rbfrdtke4rjh1uu2319ts2d